Lori Anne Kunkel Sells 10,000 Shares of Enliven Therapeutics (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Lori Anne Kunkel sold 10,000 shares of the stock in a transaction on Monday, July 6th. The shares were sold at an average price of $50.49, for a total value of $504,900.00. Following the transaction, the director directly owned 41,884 shares of the company’s stock, valued at approximately $2,114,723.16. This trade represents a 19.27% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Lori Anne Kunkel also recently made the following trade(s):

• On Friday, June 5th, Lori Anne Kunkel sold 10,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $34.54, for a total value of $345,400.00.

Enliven Therapeutics Price Performance

Shares of NASDAQ ELVN opened at $52.18 on Friday. The stock has a market capitalization of $3.18 billion, a PE ratio of -31.25 and a beta of 0.24. Enliven Therapeutics, Inc. has a one year low of $14.78 and a one year high of $52.39. The business’s fifty day moving average price is $43.13 and its 200-day moving average price is $34.62.

Enliven Therapeutics (NASDAQ:ELVN) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.06. As a group, equities analysts expect that Enliven Therapeutics, Inc. will post -1.63 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on ELVN shares. Stifel Nicolaus upped their price target on shares of Enliven Therapeutics from $60.00 to $80.00 and gave the company a “buy” rating in a research note on Wednesday, July 1st. Guggenheim began coverage on shares of Enliven Therapeutics in a research note on Tuesday, May 12th. They issued a “buy” rating and a $80.00 price objective for the company. Wall Street Zen raised shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, May 11th. JonesTrading boosted their target price on shares of Enliven Therapeutics from $45.00 to $70.00 and gave the company a “buy” rating in a report on Monday, June 29th. Finally, Mizuho raised their price target on Enliven Therapeutics from $45.00 to $62.00 and gave the stock an “outperform” rating in a report on Tuesday, June 2nd. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $69.17.

Institutional Trading of Enliven Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Enliven Therapeutics by 8.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,729 shares of the company’s stock worth $428,000 after purchasing an additional 1,693 shares during the period. Goldman Sachs Group Inc. grew its position in Enliven Therapeutics by 61.3% during the first quarter. Goldman Sachs Group Inc. now owns 211,752 shares of the company’s stock worth $4,167,000 after buying an additional 80,506 shares in the last quarter. Jane Street Group LLC bought a new position in Enliven Therapeutics in the 1st quarter worth about $578,000. Legal & General Group Plc raised its holdings in shares of Enliven Therapeutics by 52.2% in the 2nd quarter. Legal & General Group Plc now owns 32,225 shares of the company’s stock valued at $646,000 after acquiring an additional 11,058 shares in the last quarter. Finally, Quantbot Technologies LP boosted its position in shares of Enliven Therapeutics by 47.1% during the 2nd quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock valued at $90,000 after acquiring an additional 1,434 shares during the last quarter. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.